PanTherapeutics, Rte de Lavaux 49, 1095 Lutry, Switzerland.
Future Microbiol. 2020 Oct;15(15):1507-1521. doi: 10.2217/fmb-2020-0174. Epub 2020 Nov 3.
The rapid spread of SARS-CoV-2 leading to the COVID-19 pandemic with more than 400,000 deaths worldwide and the global economy shut down has substantially accelerated the research and development of novel and efficient COVID-19 antiviral drugs and vaccines. In the short term, antiviral and other drugs have been subjected to repurposing against COVID-19 demonstrating some success, but some excessively hasty conclusions drawn from significantly suboptimal clinical evaluations have provided false hope. On the other hand, more than 300 potential therapies and at least 150 vaccine studies are in progress at various stages of preclinical or clinical research. The aim here is to provide a timely update of the development, which, due to the intense activities, moves forward with unprecedented speed.
新冠病毒（SARS-CoV-2）的快速传播导致了 COVID-19 大流行，全球有超过 40 万人死亡，全球经济陷入停滞，这极大地加速了新型、有效的 COVID-19 抗病毒药物和疫苗的研发。短期内，抗病毒药物和其他药物已被用于治疗 COVID-19，取得了一些成功，但一些从明显不充分的临床评估中得出的过于仓促的结论带来了错误的希望。另一方面，有超过 300 种潜在的治疗方法和至少 150 种疫苗研究正在进行，处于临床前或临床研究的不同阶段。本文旨在及时更新进展情况，由于活动十分密集，开发工作正以前所未有的速度推进。
